|
127 Companies |
|
123 Products |
|
123 Products |
|
59 Mechanisms of Action |
|
6 Trials |
|
3245 News |
|
| «12...5152535455565758596061...6566» |
- Trial completion: A Study to Evaluate Safety and Immunogenicity of AERAS-402 (clinicaltrials.gov) - Nov 11, 2012
P1, N=12, Completed, Sponsor: Aeras
Active, not recruiting --> Completed
- | Trial completion: Safety and Immunogenicity of AERAS-402 in HIV-infected, Bacillus Calmette-Guerin (BCG)-Vaccinated Adults (clinicaltrials.gov) - Nov 11, 2012
P2, N=26, Completed, Sponsor: Aeras
Active, not recruiting --> Completed Recruiting --> Completed
- |||||||||| New P3 trial: Immunogenicity and Safety of Meningococcal ACWY Conjugate Vaccine in Healthy Children, Adolescents and Adults in Russia (clinicaltrials.gov) - Nov 8, 2012
P3, N=198, Completed, Sponsor: Novartis Vaccines
- |||||| Trumenba (meningococcal B vaccine) / Pfizer
Enrollment open: A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years (clinicaltrials.gov) - Nov 7, 2012
P3, N=5700, Recruiting, Sponsor: Pfizer
Recruiting --> Completed Not yet recruiting --> Recruiting
- Isentress (raltegravir) / Merck (MSD)
Trial completion, Combination therapy: Efficacy and Safety of 2 Raltegravir Doses in Naive HIV-1-infected Patients Receiving Rifampin for Active Tuberculosis (clinicaltrials.gov) - Nov 6, 2012
P2, N=155, Completed, Sponsor: French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: PROTETEC: The Effect of Probiotics on E. Coli-induced Gastroenteritis (clinicaltrials.gov) - Nov 5, 2012
P=N/A, N=60, Completed, Sponsor: NIZO Food Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| Trial completion: Evaluating the Comparative Safety and Immunogenicity of Three Lots of Novartis Meningococcal C Conjugate Vaccine in Healthy Toddlers (clinicaltrials.gov) - Nov 5, 2012
P2, N=992, Completed, Sponsor: Novartis
Active, not recruiting --> Completed Active, not recruiting --> Completed
- || Biomarker, New P3 trial: Pharmacogenetics of Vitamin D Supplementation in Tuberculosis (clinicaltrials.gov) - Nov 4, 2012
P3, N=62, Completed, Sponsor: University of Birmingham
- ||||| Trumenba (meningococcal B vaccine) / Pfizer
Enrollment change: A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years (clinicaltrials.gov) - Nov 4, 2012
P3, N=5700, Recruiting, Sponsor: Pfizer
Active, not recruiting --> Completed N=7500 --> 5700
- || azithromycin / Generic mfg.
New P3 trial: Antibiotic Steroid Combination Compared With Individual Administration in the in the Treatment of Ocular Inflammation and Infection (clinicaltrials.gov) - Nov 4, 2012
P3, N=60, Not yet recruiting, Sponsor: Adapt Produtos Oftalmol
- ondansetron / Generic mfg.
New P2 trial: ITT-MAC: Improving Tolerance of Treatment of Pulmonary MAC Infections (clinicaltrials.gov) - Oct 30, 2012
P2, N=0, Withdrawn, Sponsor: University of Florida
- |||||||||| New P3 trial: Persistence of Antibody Levels and Response to Fifth or Third Meningococcal B Recombinant Vaccine in 4-year Old Healthy Children Who Previously Participated in Study V72P12E1 (clinicaltrials.gov) - Oct 28, 2012
P3, N=805, Completed, Sponsor: Novartis Vaccines
- Arcalyst (rilonacept) / Regeneron, Kiniksa
Trial completion: Rilonacept for Treatment of Familial Mediterranean Fever (FMF) (clinicaltrials.gov) - Oct 28, 2012
P2, N=14, Completed, Sponsor: The Cleveland Clinic
N=7500 --> 5700 Active, not recruiting --> Completed
- azithromycin / Generic mfg.
Trial completion: Trachoma Elimination Follow-up (clinicaltrials.gov) - Oct 28, 2012
P4, N=20000, Completed, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed Active, not recruiting --> Completed
- oral live-attenuated Shigella sonnei vaccine (WRSs2) / National Institute of Allergy and Infectious Diseases
Enrollment open: Safety and Immunogenicity of Two Live, Attenuated Oral Shigella Sonnei Vaccines: WRSs2 and WRSs3 (clinicaltrials.gov) - Oct 24, 2012
P1, N=90, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- azithromycin / Generic mfg.
Trial completion: Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy (clinicaltrials.gov) - Oct 23, 2012
P=N/A, N=636, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | New P4 trial: Tdap Vaccine in Post-Partum Women (clinicaltrials.gov) - Oct 18, 2012
P4, N=55, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- | Enrollment closed: Early Antiretroviral Treatment and/or Early Isoniazid Prophylaxis Against Tuberculosis in HIV-infected Adults (ANRS 12136 TEMPRANO) (clinicaltrials.gov) - Oct 18, 2012
P3, N=2073, Active, not recruiting, Sponsor: French National Agency for Research on AIDS and Viral Hepatitis
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- | rifampicin / Generic mfg.
Trial completion: Tuberculosis Prevention for HIV Infected Adults (clinicaltrials.gov) - Oct 18, 2012
P3, N=1148, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment open: Study of Complication Rates Associated With PICC for Left vs Right (clinicaltrials.gov) - Oct 17, 2012
P=N/A, N=200, Recruiting, Sponsor: McGill University Health Center
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: Computer-Assisted Self-Interviews and Health Screening in the Pediatric Emergency Department (clinicaltrials.gov) - Oct 14, 2012
P=N/A, N=801, Completed, Sponsor: Washington University School of Medicine
- | New P1 trial: To Determine the Safety and Immunogenicity of an Oral(Whole Cell) Euvichol Cholera Vaccine in Healthy Adult Men (clinicaltrials.gov) - Oct 14, 2012
P1, N=20, Completed, Sponsor: EuBiologics Co.,Ltd
- Enrollment closed: Tuberculosis in China (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=210, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- |||| Trial completion, Pneumococcal vaccines: 6114A1-4000-CN: A Study To Assess The Safety And Effectiveness Of Prevenar In Chinese Children Who Have Not Previously Received A Vaccine Against Pneumococcal Bacteria (clinicaltrials.gov) - Oct 11, 2012
P4, N=505, Completed, Sponsor: Pfizer
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Kineret (anakinra) / SOBI
New P3 trial: Kineret (Anakinra), in Adult Patients With Colchicine-Resistant Familial Mediterranean Fever (clinicaltrials.gov) - Oct 10, 2012
P3, N=50, Recruiting, Sponsor: Sheba Medical Center
- lanopepden (GSK1322322) / GSK
Trial completion: A Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C -GSK1322322 After an Intravenous and an Oral Dose (clinicaltrials.gov) - Oct 10, 2012
P1, N=5, Completed, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial initiation date, Adherence: Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT (clinicaltrials.gov) - Oct 9, 2012
P3, N=1000, Recruiting, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Initiation date: Jun 2012 --> Sep 2012
- | Enrollment open, Adherence: Study 33: Adherence to Latent Tuberculosis Infection Treatment 3HP SAT Versus 3HP DOT (clinicaltrials.gov) - Oct 9, 2012
P3, N=1000, Recruiting, Sponsor: Centers for Disease Control and Prevention
Initiation date: Jun 2012 --> Sep 2012 Not yet recruiting --> Recruiting
- acetylcysteine solution / Generic mfg.
Trial completion: N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement (clinicaltrials.gov) - Oct 9, 2012
P2, N=60, Completed, Sponsor: Assiut University
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- | Stelara (ustekinumab) / J&J
New P2 trial: A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa (clinicaltrials.gov) - Oct 9, 2012
P2, N=20, Active, not recruiting, Sponsor: University Medical Centre Groningen
- | Cubicin (daptomycin) / Merck (MSD)
Trial termination: RENSE: Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (clinicaltrials.gov) - Oct 8, 2012
P4, N=92, Terminated, Sponsor: Cubist Pharmaceuticals
Not yet recruiting --> Completed Recruiting --> Terminated; Cubist has reached an agreement with the FDA that enrollment in the DAP-RENSE-08-05 study can stop.
- Cubicin (daptomycin) / Merck (MSD)
Enrollment change: RENSE: Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment (clinicaltrials.gov) - Oct 8, 2012
P4, N=92, Terminated, Sponsor: Cubist Pharmaceuticals
Recruiting --> Terminated; Cubist has reached an agreement with the FDA that enrollment in the DAP-RENSE-08-05 study can stop. N=120 --> 92
- | acetylcysteine solution / Generic mfg.
New P2 trial: N-acetylcysteine for Renal Protection in Patients With Rheumatic Heart Disease Undergoing Valve Replacement (clinicaltrials.gov) - Oct 8, 2012
P2, N=60, Completed, Sponsor: Assiut University
- |||| Cubicin (daptomycin) / Merck (MSD)
Trial completion, HEOR: DAPHEOR1006: Daptomycin Versus Vancomycin in Participants With Skin Infections Due to MRSA (clinicaltrials.gov) - Oct 8, 2012
P4, N=250, Completed, Sponsor: Cubist Pharmaceuticals
N=120 --> 92 Recruiting --> Completed
- Trial initiation date: Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) (clinicaltrials.gov) - Oct 7, 2012
P2, N=40, Recruiting, Sponsor: Michael Boyle
Recruiting --> Completed Initiation date: Jul 2012 --> Oct 2012
- Enrollment open: Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP) (clinicaltrials.gov) - Oct 7, 2012
P2, N=40, Recruiting, Sponsor: Michael Boyle
Initiation date: Jul 2012 --> Oct 2012 Not yet recruiting --> Recruiting
- | biapenem / Generic mfg.
New P1 trial: Safety, Tolerability, Pharmacokinetics of Intravenous RPX2003 (Biapenem) in Healthy Adult Subjects (clinicaltrials.gov) - Oct 4, 2012
P1, N=36, Completed, Sponsor: Rempex Pharmaceuticals
- ||||| ceftaroline fosamil / Generic mfg.
New P4 trial: Safety and Efficacy Study of Ceftaroline in Subjects With Staphylococcus Aureus Bacteremia or With Persistent Methicillin-Resistant Staphylococcus Aureus Bacteremia (clinicaltrials.gov) - Oct 3, 2012
P4, N=60, Active, not recruiting, Sponsor: Cerexa, Inc.
- | New P2 trial: Safety, Tolerability, and Immunogenicity Study of Investigational Recombinant Botulinum Vaccine A/B (rBV A/B) in Volunteers Previously Immunized With Investigational Pentavalent Botulinum Toxoid (clinicaltrials.gov) - Oct 3, 2012
P2, N=83, Enrolling by invitation, Sponsor: California Department of Public Health
- | Trial completion: PRETEC: The Effect of Probiotics on E. Coli Gastroenteritis (clinicaltrials.gov) - Oct 1, 2012
P=N/A, N=40, Completed, Sponsor: NIZO Food Research
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | sodium phenylbutyrate / Generic mfg.
New P2 trial: IRETB: Immune Reconstitution in Tuberculosis Disease (clinicaltrials.gov) - Oct 1, 2012
P2, N=300, Recruiting, Sponsor: Karolinska Institutet
- | New P2 trial: ProVIP: Probiotic Therapy for the Reversal of Bacterial Vaginosis in Pregnancy (clinicaltrials.gov) - Sep 30, 2012
P2, N=86, Completed, Sponsor: Mount Sinai Hospital, Canada
- Trial initiation date: Implementation of an Efficacious Intervention for High Risk Women in Mexico (clinicaltrials.gov) - Sep 26, 2012
P=N/A, N=1080, Recruiting, Sponsor: University of California, San Diego
Active, not recruiting --> Completed Initiation date: Jan 2011 --> Nov 2011
- PREVNAR 13 (pneumococcal 13-valent conjugate vaccine) / Pfizer
Enrollment open: A Phase IIb, Open-Label, Dose Ranging Study of 13-Valent Pneumococcal Conjugate Vaccine in Adults 55 Through 74 Years of Age Previously Vaccinated With 23-Valent Pneumococcal Polysaccharide Vaccine (clinicaltrials.gov) - Sep 26, 2012
P2b, N=882, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Initiation date: Jan 2011 --> Nov 2011 Not yet recruiting --> Recruiting
- |||||| Nimenrix (MenACWY-TT) / Pfizer
Enrollment open: Comparison of GlaxoSmithKline (GSK)134612 in Subjects With Increased Risk for Meningococcal Disease Versus Healthy Subjects (clinicaltrials.gov) - Sep 26, 2012
P3, N=100, Recruiting, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Trial completion: CDC Anthrax Vaccine Clinical Trial (clinicaltrials.gov) - Sep 26, 2012
P4, N=1560, Completed, Sponsor: Centers for Disease Control and Prevention
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Trial completion: Nucleic Acid Amplification Tests (NAATs) for the Diagnosis of Pharyngeal and Rectal Chlamydia and Gonorrhea Infections (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=3900, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: The Participant Agreement for Contact Tracing (PACT) Study: Enhancing Partner Notification Services. (clinicaltrials.gov) - Sep 25, 2012
P1/2, N=494, Completed, Sponsor: Centers for Disease Control and Prevention
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: Long-term Impact of Pneumococcal Conjugate Vaccine on Carriage (clinicaltrials.gov) - Sep 24, 2012
P=N/A, N=1000, Completed, Sponsor: Johns Hopkins Bloomberg School of Public Health
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||| Enrollment change: Antibody Persistence to REVAXIS or DT Polio and Immune Response to TETRAVAC-ACELLULAIRE (clinicaltrials.gov) - Sep 23, 2012
P4, N=278, Completed, Sponsor: Sanofi Pasteur MSD
Active, not recruiting --> Completed N=532 --> 278